Nurix Therapeutics Inc
nurixtx.comNurix Therapeutics Inc (NASDAQ: NRIX) is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation (TPD) drug candidates for cancer and inflammatory diseases. Revenue comes from collaboration agreements with pharmaceutical partners, including upfront payments, research funding, milestones, and royalties, rather than from commercial drug sales. Partners as of the 10-K filed January 28, 2026 include Gilead Sciences, Sanofi, and Pfizer. Nurix's lead wholly owned clinical asset is NX-2127, with NX-1607 also in Phase 1a/1b dose escalation across solid tumor indications. Gilead has licensed the IRAK4 TPD program, with FDA IND clearance for GS-6791/NX-0479 announced April 2025. Sanofi licensed development candidate NX-3911 in June 2025 and a second undisclosed program in May 2025. The company has not generated revenue from commercial product sales and discloses going-concern considerations. Operating lease commitments totaled approximately $82.5 million as of November 30, 2025, with facilities in The Woodlands, Texas and Brisbane, California. Arthur T. Sands, M.D., Ph.D. serves as President and CEO.
Products & Services
Targeted protein degradation (TPD) drug candidates: NX-2127 (wholly owned, clinical stage), NX-1607 (Phase 1a/1b, solid tumors), GS-6791/NX-0479 (IRAK4 degrader, partnered with Gilead, IND cleared April 2025), NX-3911 (licensed to Sanofi, IND-enabling studies commenced June 2025), and additional undisclosed programs in lead optimization and IND-enablement with Gilead, Sanofi, and Pfizer.
Revenue Model
Collaboration and license agreements with Gilead, Sanofi, and Pfizer, structured as upfront payments, research funding, development milestones, and royalties. No commercial product sales revenue as of the 10-K filed January 28, 2026.
Customers & Markets
Pharmaceutical partners (Gilead Sciences, Sanofi, Pfizer) are the direct revenue customers. End therapeutic markets are oncology (hematologic malignancies, solid tumors) and inflammatory/immune diseases.
Geographic Exposure
Operations in The Woodlands, Texas and Brisbane, California as of the 10-K filed January 28, 2026. Operating lease commitments of approximately $82.5 million as of November 30, 2025.
Financial Snapshot
Loading...
